New COVID19 Outpatients Study Backs Claims for HCQ+ZPac Protocol

Written by John O'Sullivan on October 29, 2020. Posted in Current News

New study published this week in the International Journal of Antimicrobial Agents has shown that Hydroxychloroquine at low dose in combination with zinc and azithromycin proved to be an effective therapeutic approach against COVID-19.

Researchers conducted this first published COVID-19 outpatient study based on risk stratification and early antiviral treatment at the beginning of the disease. What the study found was that the combination of these three components into one treatment protocol significantly reduced hospitalization rates in the treatment group.

The full paper,’COVID-19 outpatients – early risk-stratified treatment with zinc plus low dose hydroxychloroquine and azithromycin: a retrospective case series study‘ may be accessed online here. [1]

Selected excerpts are shown below:

ABSTRACT

Objective

To describe outcomes of patients with coronavirus disease 2019 (COVID-19) in the outpatient setting after early treatment with zinc, low dose hydroxychloroquine, and azithromycin (triple therapy) dependent on risk stratification.

Design

Retrospective case series study.

Setting

General practice.

Participants

141 COVID-19 patients with laboratory confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in the year 2020.

Main outcome measures

Risk-stratified treatment decision, rate of hospitalization and all-cause death.

Results

After 4 days (median, IQR 3-6, available for N=66/141) of onset of symptoms, 141 patients (median age 58 years, IQR 40-67; 73% male) received a prescription for the triple therapy for 5 days. Independent public reference data from 377 confirmed COVID-19 patients of the same community were used as untreated control. 4 of 141 treated patients (2.8%) were hospitalized, which was significantly less (p<0.001) compared with 58 of 377 untreated patients (15.4%) (odds ratio 0.16, 95% CI 0.06-0.5). One patient (0.7%) died in the treatment group versus 13 patients (3.5%) in the untreated group (odds ratio 0.2, 95% CI 0.03-1.5; p=0.12). There were no cardiac side effects.

[1] See: https://doi.org/10.1016/j.ijantimicag.2020.106214

Read more at www.sciencedirect.com

Please Donate Below To Support Our Ongoing Work To Expose The Lies About COVID19

About the author: John O’Sullivan John is CEO and co-founder (with Dr Tim Ball) of Principia Scientific International (PSI).  John is a seasoned science writer and legal analyst who assisted Dr Ball in defeating world leading climate expert, Michael ‘hockey stick’ Mann in the ‘science trial of the century‘. O’Sullivan is credited as the visionary who formed the original ‘Slayers’ group of scientists in 2010 who then collaborated in creating the world’s first full-volume debunk of the greenhouse gas theory plus their new follow-up book.

PRINCIPIA SCIENTIFIC INTERNATIONAL, legally registered in the UK as a company incorporated for charitable purposes. Head Office: 27 Old Gloucester Street, London WC1N 3AX. 

Please DONATE TODAY To Help Our Non-Profit Mission To Defend The Scientific Method.

Trackback from your site.